The atomistic level structure for the activated human κ-opioid receptor bound to the full Gi protein and the MP1104 agonist by Mafi, Amirhossein et al.
The atomistic level structure for the activated human
κ-opioid receptor bound to the full Gi protein
and the MP1104 agonist
Amirhossein Mafia, Soo-Kyung Kima, and William A. Goddard IIIa,1
aMaterials and Process Simulation Center, California Institute of Technology, Pasadena, CA 91125
Contributed by William A. Goddard III, January 22, 2020 (sent for review June 11, 2019; reviewed by Krzysztof Palczewski and Nagarajan Vaidehi)
The kappa opioid receptor (κOR) is an important target for pain
therapeutics to reduce depression and other harmful side effects
of existing medications. The analgesic activity is mediated by κOR
signaling through the adenylyl cyclase-inhibitory family of Gi pro-
tein. Here, we report the three-dimensional (3D) structure for the
active state of human κOR complexed with both heterotrimeric Gi
protein and MP1104 agonist. This structure resulted from long
molecular dynamics (MD) and metadynamics (metaMD) simula-
tions starting from the 3.1-Å X-ray structure of κOR–MP1104 after
replacing the nanobody with the activated Gi protein and from the
3.5-Å cryo-EM structure of μOR–Gi complex after replacing the 168
missing residues. Using MD and metaMD we discovered interac-
tions to the Gi protein with strong anchors to two intracellular
loops and transmembrane helix 6 of the κOR. These anchors
strengthen the binding, contributing to a contraction in the bind-
ing pocket but an expansion in the cytoplasmic region of κOR to
accommodate G protein. These remarkable changes in κOR struc-
ture reveal that the anchors are essential for activation.
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Treatment of chronic neuropathic pain is a major challenge inclinical practice (1), because many patients do not experience
sufficient pain relief with medications while others experience
serious side effects (2). Opioid analgesics such as morphine are
strong painkillers, activating opioid receptors in the central
nervous system to inhibit pain signals. However, they are not
recommended as first-line medications because they evoke such
side effects as sedation, physical dependence, addiction, toler-
ance, and respiratory depression (2). While G protein-mediated
signaling is thought to confer analgesia, the potentially lethal
side effects of opioids such as fatal respiratory depression are
thought to be mainly mediated by μ-opioid receptor (μOR) sig-
naling through the β-arrestin pathway (2). To avoid the side ef-
fects associated with arrestin signaling, tremendous efforts are
being made to design biased analgesics that favor only G protein-
mediated signaling (3). Alternatively, the κ-opioid receptor
(κOR) is an important target for developing new pain and de-
pression therapeutics that attenuate the side effects associated
with μOR agonists, particularly respiratory depression (4, 5). In
particular, μOR and κOR stimulate signaling via the adenylyl cyclase-
inhibitory family of G proteins (Gi/o), leading to the analgesic activity
(6). Therefore, the detailed interplay between κOR, Gi protein, and a
ligand that results in Gi protein activation is crucial for the design of
new analgesics. In fact, a major challenge is distinguishing whether a
designed ligand serves as an agonist or antagonist. To overcome this
challenge, structure-based ligand design can be used to optimize in-
teractions between κOR–Gi–ligand in the active state. Unfortunately,
no active state κOR–Gi complex has yet been obtained, hindering the
deep understanding of signaling needed to develop new ligands.
We report here this structure: the optimized active state
structure for human κOR complexed with full heterotrimeric
Gi protein and the high-affinity MP1104 agonist. This three-
dimensional (3D) structure should be useful for in silico design
of agonists with higher activity and it provides the basis for a
deeper understanding of G protein activation.
To predict the structure for this complex we started with the
recent 3.1-Å resolution crystal structure of the κOR active state
bound to a high-affinity agonist MP1104. This structure was
stabilized in the active state with a nanobody (Nb39) (7).
Moreover, the resolution of 3.1 Å did not allow identification of
31 amino acid side chains that likely are important (seeMethods)
in recruiting Gi protein. In addition, to obtain the crystal struc-
ture of κOR, several modifications were made to facilitate
crystallization (7). The most striking modification is the re-
placement of the intracellular loop 3 (ICL3) with a T4 lysozyme
(T4L) protein that stabilized the basal activity of G protein-
coupled receptors (GPCRs). It has been shown that altering
or mutating residues in the ICL3 of GPCR seems to modify
their G protein selectivity, leading to dramatically decreas-
ing transducing activation (8). For instance, mutation of the wild-
type sequence from “234AQQQESATTQKAEKEV250” to
“
234ATSLHGYSVTGPTGSNL250” reduces the transducing acti-
vation by 91% in the bovine rhodopsin (8). However, the stimu-
lation of adenylyl cyclase increased by 40% (9) in a chimeric
human A2a adrenergic receptor where the wild-type sequence of
“
174K-L396” including all residues on the ICL3, “234R-W362,” were
replaced with the wild-type sequence “214I-V295” of human β2
adenosine receptor. Therefore, we speculate that ICL3 of κOR
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similarly serves a significant role in signaling. Notably, activated
GPCRs stabilized by Nbs also differ from those stabilized by their
cognate heterotrimeric G protein. Previous observations indicate
that GPCRs stabilized by their cognate G proteins undergo a
further expansion in their cytoplasmic region in order to open up
the space large enough to accommodate G protein α5 helix (10–13).
Therefore, regardless of having the active state complex of
κOR–MP1104–Nb39, we still need the structure of κOR attached
to its cognate G protein to understand the G protein activation
mediated by binding of the agonist to κOR.
To obtain the 3D structure for human κOR, we used the active
state human κOR–MP1104–Nb39 complex (7) (Protein Data
Bank [PDB] ID: 6B73) as the template. However, we removed
the Nb39, oleic acid, and the cholesterol resolved in the crystal
complex. Then, we replaced the engineered κOR N terminus
amino acids with the native residues. This was followed by op-
timizing the side chains of κOR using the SCREAM method
(side-chain rotamer excitation analysis method), which provides
an efficient way to orient the residues on different chains for
maximal hydrogen bonding (14). The three close subtypes of
opioid receptors, including μOR, κOR, and δOR, have 70%
identity in the structure of their transmembrane (TM) domains
(15). Thus, we used the recent 3.5-Å resolution cryo-EM struc-
ture of mouse μOR–DAMGO–nucleotide-free Gi (13) as a
template to insert the Gi protein in the κOR–MP1104 complex.
To do this, the human κOR–MP1104 was superimposed onto the
cryo-EM mouse μOR. However, the mouse μOR–Gi cryo-EM
structure did not resolve important amino acid residues 56 to 181
or residues 234 to 240 of the Gαi-alpha helical (AH) domain nor
did it resolve the full side chains for several amino acid residues
(see Methods), including Gαi-E28, E308, E318, and Gβi-D312
that we find to play an important role in coupling the Gi pro-
tein to the κOR. Therefore, we built in the AH domain from the
recent cryo-EM structure of human rhodopsin complexed with
the Gi protein (PDB ID: 6CMO) (16). The side chains in the
resulting complex were optimized to maximize the number of
interactions between κOR and Gi. Finally, we performed several
short (16 to ∼120 ns) molecular metadynamics (metaMD) sim-
ulations to find the best pair for each unsatisfied charged residue
with the idea of strengthening the interactions between κOR and
Gi protein. Then, we examined the stability of interactions and
structure by performing classical molecular dynamics (MD)
simulations with full membrane and solvent.
We find that the presence of Gi protein alters the binding of
MP1104, but it does not change the affinity. A slight change in
the binding pose of MP1104 takes place with a further contrac-
tion in the κOR extracellular and further expansion in the κOR
intracellular region. These changes in the structure are con-
sistent with the general activation mechanism proposed for class
AGPCRs, where the contraction in the extracellular region of GPCR
is associated with expansion in the intracellular region of GPCRs.
However, we discovered that the Gi protein forms strong anchors to
ICL1, ICL2, and the cytoplasmic end of TM6. We find that the
contraction in the binding site is mostly due to the anchor from the Gi
protein to the ICL1 of κOR. In addition, these anchors seem to
position the Gαi5 helix so that upon activation it can ascend into
the κOR to establish extensive interactions with κOR. We also
find that interactions from these anchors and Gαi5 helix to the
κOR cause a further expansion in the cytoplasmic region. These
findings suggest that strong anchors and Gαi5 interactions with
GPCR are essentials for activation and signaling.
Results
Comparison of the Active State κOR–Gi with κOR–Nb39.A full overview
of the human κOR–Gi protein–MP1104 complex immersed in the
lipid bilayer is shown in SI Appendix, Fig. S1. Fig. 1 compares the
final structure for the human κOR–MP1104 agonist–nucleotide-
free Gi (17) with the active state of the engineered κOR bound
to MP1104 agonist stabilized by Nb39. The overall root mean square
displacement (RMSD) of TMCα helices between κOR–Gi and κOR–
Nb39 is about 1.7 Å (SI Appendix, Table S1) where the pres-
ence of Gi protein leads to 5.3-Å movement, measuring the
distance between Y1192.64-CακOR-Gi protein (the superscript is
Ballesteros–Weinstein numbering for GPCRs) (18), taken from ref.
19) and Y1192.64-CακOR-Nb39, of the extracellular (EC) portion of
TM2 toward the receptor core (Fig. 1A). This movement reduces the
volume of binding site from 904.2 Å3 (crystal structure) to 859.4 Å3.
We attribute this contraction in the binding site mostly to the
strong interaction from Gβi subunit to ICL1 of κOR. To find that
such movement of TM2 is statistically significant, we repeated our
200 ns of MD simulations with the Amber14 force field three times
using different velocities. We find that in all of our calculations,
TM2 tends to move toward the receptor core (SI Appendix, Fig. S2
A–C). To eliminate the possibility that this contraction in the
binding site resulted only from the MD simulation, we also carried
out a 200-ns MD simulation on the crystal structure of κOR–Nb39
(Fig. 2A). However, since T4L was not resolved and not provided
in the crystal structure, we had to replace it with the native ICL3
over the course of the MD simulation. We find that the overall
RMSD of TMCα domains between our optimized κOR–Nb39
structure and the crystal structure of κOR–Nb39 is about 1.3 Å.
Nonetheless, comparing the optimized structures of κOR–Gi and
κOR–Nb39 reveals that Gi protein causes a further 3.6-Å move-
ment of TM2 toward the receptor core (Fig. 2B), which conse-
quently contracts the binding site. Finally, to eliminate the probable
effects of our chosen force field, we performed a 150-ns MD
simulation on the κOR–Gi–MP1104 complex using Charmm36m,
which resulted in RMSD= 2.0 Å compared to the crystal κOR–Nb39
complex. Interestingly, a different force field, here Charmm36m,
also confirms that Gi protein imposes a 7.4-Å movement of TM2
toward the core, which consequently induces additional contraction
in the extracellular domain of κOR (Fig. 2C). Thus, despite the
force field type, our simulations show that the direct interaction
from the Gβi subunit to the ICL1 of κOR causes a pronounced
contraction in the binding site.
In addition, we find that interaction between the Gi protein
and κOR forces the cytoplasmic segment of TM6 to make a 3.2-Å
lateral displacement toward TM7. This leads to opening up the
space between TM3 and TM6 (Fig. 1B) from 13.7 to 16.9 Å
(measuring the distance between K265-Cα and V160-Cα), sug-
gesting that this further 3.2-Å lateral displacement is essential to
accommodate the Gαi5 helix. To find that the expansion in the
cytoplasmic region of κOR in the presence of Gi protein is sta-
tistically significant, we repeated our 200-ns MD simulations with
the Amber14 force field three times using different velocities.
We find that in all of our calculations, TM6 tends to move away
from the TM3 which eventually opens up the space in the re-
ceptor core that facilitates Gi protein recruitment (SI Appendix,
Fig. S2 D–F). To ensure that this remarkable change in the cy-
toplasmic region of κOR is not an artifact of the Amber14 force
field, we independently carried out a 150-ns MD simulation on
the κOR–Gi complex using Charmm36m (SI Appendix, Fig. S3).
Strikingly, our calculation confirms that Gi protein indeed im-
poses a pronounced change in the κOR structure that ends up
with opening up the space between TM3 and TM6 from 13.7 to
16.3 Å (Fig. 2D) to accommodate Gαi5 helix. This behavior is
consistent with previous observations (10–13) that reveal the
cytoplasmic end of TM6 in β2 adenosine receptor and μOR
structures activated by G protein has a further outward dis-
placement compared to the ones stabilized by Nb (10, 11). No-
tably, the latter has a similar 3-Å lateral movement toward TM7,
which is consistent with our findings for κOR. Overall, these dra-
matic changes in the κOR structure are consistent with the general
activation mechanism proposed for class A GPCRs (20–23) where
contraction in the extracellular region of the GPCR is associated
with further expansion in the intracellular region of GPCRs.
Mafi et al. PNAS | March 17, 2020 | vol. 117 | no. 11 | 5837
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An important criterion is to compare the conformations of
such highly conserved residues as N7.49P7.50XXY7.53 as well as
I3.40, D3.49, R3.50, Y3.51, P5.50, and F6.44 motifs that have been
suggested to be important for GPCR activation (24). Our active
state structure of the κOR–Gi protein–agonist complex leads to
nearly identical conformations for these highly conserved amino
acids in the active state stabilized by Nb39 (7) (Fig. 1C). Of these
residues, only the conformation of R156 differs slightly between
these two structures, because it establishes a polar interaction
with C351 in Gαi5 helix in our structure.
Structure of κOR–Gi Complex. A strong polar interaction couples
ICL2 of κOR to the αN-β1 loop of Gi protein. The overview of
the human κOR–Gi protein–MP1104 complex is described in
Fig. 3 along with some important interactions shown in SI Ap-
pendix, Fig. S4. We find that D168 on ICL2 forms a strong and
stable salt bridge with R32 on the GαN-β1 loop of Gαi (Fig. 3B
and SI Appendix, Fig. S4B). This ionic coupling is an anchor that
coordinates ICL2 to create a network of extensive salt bridges
and hydrogen bonds with the Gαi5 helix (Fig. 3C). It is well
known that the extensive interactions from the Gαi5 helix to the
receptor play a pivotal role in G protein binding (25–28). We
performed three independent 200-ns MD simulations with
Amber14 to examine whether the emergence of this salt bridge is
statistically important. Interestingly, we find that all of our sim-
ulations feature the strong and stable anchors from R32 on
the GαN-β1 loop of Gαi to D168 on ICL2 (SI Appendix, Fig. S2
G–I). To eliminate the probable effects of the force field, we also
carried out a separate 150-ns MD simulation using the Charmm36m
force field (SI Appendix, Fig. S3) to find that D168ICL2 engages
in an ionic interaction with the R32GαN-β1 loop (SI Appendix, Fig.
S3C). The D168 residue in ICL2 is conserved in μOR, κOR, and
δOR (SI Appendix, Table S2) (19). To examine whether the μOR–Gi
complex also features the same strong couplings, and most im-
portantly to test whether our proposed procedure is able to predict
high-resolution complexes of G protein–GPCR–agonist for those
GPCRs that were already crystalized and stabilized by a nanobody,
we built a new active state structure of mouse μOR–BU72–Gi
protein by replacing the Nb39 of the crystal structure (PDB ID:
5C1M) (12) with the Gi protein. Then we optimized this structure
in a similar fashion as we described for the κOR–MP1104–Gi
complex (SI Appendix, Figs. S5 and S6). Strikingly, we find that our
model of μOR–BU72–Gi features strong anchoring between the
analogous Asp residue in μOR and R32 in the GαN-β1 loop of
Gαi (SI Appendix, Fig. S6B), which induces the Gαi5 helix to en-
gage in extensive interactions with the mouse μOR. To ensure that
Gi protein binds to the mouse μOR by forming strong salt bridges
to the ICL2, we also optimized the cryo-EM μOR–DAMGO–Gi
structure (SI Appendix, Fig. S7). Our optimized cryo-EM structure
of μOR–DAMGO–Gi confirms that μOR recruits Gi protein by
forming strong anchors from the ICL2. These findings show that
the anchor between ICL2 and Gi protein is essential for stabilizing
the active state complex of opioid receptors.
Our MD simulations find that Gβi also makes a direct ionic
contact to the ICL1 of κOR (Fig. 3D). A charge–charge interaction
is formed between D312Gβi and K89ICL1 (SI Appendix, Fig. S4H)
that remains stable during the course of our MD simulation.
Forming this salt bridge coordinates D312Gβi to involve another
polar interaction with the K91ICL1 that frequently becomes a
water-mediated interaction (SI Appendix, Fig. S4I). The same di-
rect interaction between Gβi and κOR is also seen in all of our
simulations with Amber14 (Fig. 3D and SI Appendix, Fig. S2 G–I).
To examine whether the direct contact between Gβi and ICL1 of
κOR is really independent from the force field, we performed
another 150-ns MD simulation using Charmm36m. Indeed, we
find that K91ICL1 establishes a strong and stable charge–charge
interaction with D312Gβi (SI Appendix, Fig. S3B), confirming that
the Gβi subunit binds to the ICL1. Although these two Lys resi-
dues are conserved in all close subtypes of opioid receptors (SI
Appendix, Table S2), such interactions were not identified in the
cryo-EM μOR–Gi structure (13) since neither the analogous Lys
residues nor the D312Gβi were fully resolved within the 3.5-Å
resolution. However, optimizing the μOR–Gi complex (SI Ap-
pendix, Fig. S7), result to emergence of a salt bridge between
K98ICL1 and D312 Gβi (SI Appendix, Fig. S7A) in the mouse μOR–
Gi complex. Interestingly, our active state of μOR–BU72–Gi also
Fig. 1. Structural differences between our κOR stabilized by nucleotide-free Gi protein (orange) using the Amber14 force field and the crystal structure of
κOR stabilized by Nb39 (green). (A) Extracellular view. (B) Cytoplasmic view. (C) The conformation of residues in the DRY and NPxxY motifs and other key
residues of the κOR in complex with Gi protein (orange) and Nb39 (green). The Gi protein and MP1104 from the κOR–Gi protein complex, and Nb39, and
MP1104 as well T4L from the crystal structure (PDB ID: 6B73) are omitted for the sake of clarity.
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reveals that the Gβi subunit forms a strong anchor with K98ICL1
(SI Appendix, Fig. S6C). Thus, direct interactions from Gβi to the
conserved Lys residues on ICL1, a second set of anchors, likely
play important roles for signaling of opioid receptors.
Interestingly, the cryo-EM structures of the activated GLP1
receptor complexed with the Gs protein (29, 30) shows that D312
in Gβi engages in polar interactions with H171 in the ICL1 of
GLP1. Most likely H171 interacts with D312 with its protonated
state to form a salt bridge. In addition, the cryo-EM structure of
A2a adenosine receptor (A2aAR) (31) complexed with Gs pro-
tein also indicates potential polar interactions from residues S35,
N36, and Q38 of A2aAR to residues R52, D312, D333, and F335
in Gβ. These observations support our finding that D312 plays a
crucial role in coupling the Gβ to ICL1.
We find that electrostatic attractive forces are the main driving
force that couples the cytoplasmic end of TM6 to the Gαi RAS-
like region. The key interaction that regulates this coupling, is an
ionic contact between the protonated N atom of K2656.26 at the
bottom of TM6 with the negatively charged carboxylate of E318 in
Gαi–β6 region (Fig. 3E and SI Appendix, Fig. S4J). This strong
electrostatic interaction which is also seen in our other three in-
dependent simulations (SI Appendix, Fig. S2G–I), induces residues
in close proximity to form several polar interactions. For instance,
the coordinated K2566.26 tends to establish a polar interaction with
E308Gαi4, which occasionally becomes a charge–charge interaction
(Fig. 3E and SI Appendix, Fig. S4K). This attraction also induces
E308Gαi4 to form a hydrogen bond with S2626.23. On the other
hand, E308Gαi4 makes an ionic contact with the protonated N
atom of K314Gαi4-β6 loop (Fig. 3E and SI Appendix, Fig. S4 M and
O). Remarkably, these extensive polar interactions regulate both
ICL3 and TM6 to involve intense interactions with the Gαi5 helix
(Fig. 3F). Thus, we find strong polar interactions from Gi protein
to ICL3/TM6 of κOR, that constitute the third set of anchors,
stabilize the active state complex. To test that this conclusion is
independent of the force field, we performed another 150-ns MD
simulation with Charmm36m (SI Appendix, Fig. S3). We find that a
similar network of polar interactions is created between Gαi RAS-
like region and ICL3/TM6 of κOR (SI Appendix, Fig. S3D), where
the salt bridge from K2656.26 to E318 is the key interaction in this
network. Notably, the K6.26 is conserved in all close subtypes of
opioid receptors (SI Appendix, Table S2). Although we find E308
and particularly E318 establish strong interactions with TM6,
neither residue was resolved past Cβ in the recent cryo-EM μOR–
Gi complex (13). Nevertheless, the closest distance between the
E318-Cβ and the protonated N atom of μOR–K2716.26 was 4.8 Å,
suggesting these residues would likely take part in an ionic contact.
Fig. 2. MD simulations indicate that the Gi protein induces a remarkable contraction in the binding site and further expansion in the cytoplasmic region of
the κOR structure. (A) The optimized κOR (purple)–MP1104 (yellow)–Nb39 (green) complex using the Amber14 force field. This system contains ∼141 K atoms
including: proteins, ligand, 277 POPC, and ∼32,000 water molecules as well as 98 Na+ and 99 Cl−. (B) Structural comparisons, particularly the binding site,
between two optimized κOR structures stabilized by Gi protein (blue) and Nb39 (purple) using the Amber14 force field. Structural comparisons between the
optimized κOR stabilized by Gi protein (orange) using the Charmm36m force field and the crystal structure of κOR in complex with Nb39 (green): (C) ex-
tracellular view and (D) cytoplasmic view. The Gi protein, Nb39, and MP1104 as well T4L protein are removed from panels B–D for the sake of clarity.
Mafi et al. PNAS | March 17, 2020 | vol. 117 | no. 11 | 5839
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Indeed, optimization of the complex (SI Appendix, Fig. S7D) reveals
that the activated state of mouse μOR–Gi complex also features a
similar strong salt bridge interaction between K2716.26 and E318.
However, we also find that another anchor emerges between
R263ICL3 and E318 which is a common feature with our optimized
μOR–BU72–Gi structure (SI Appendix, Fig. S6D).
Our MD simulations indicate that the activated Gαi5 helix
involves extensive interactions with the conserved residues in the
cytoplasmic domain of human κOR, thereby stabilizing the
activated conformation (Fig. 3C). It is well known that the Gαi5
helix plays a pivotal role in coupling of G protein to receptors
(25–28). We find that Gαi5 binds extensively to the TM2, TM3,
and ICL2 by forming a strong network of hydrogen bonds and
salt bridges. Here, R170ICL2 plays a crucial role in maintaining
and regulating this network. R170ICL2 engages in a charge–
charge interaction with the highly conserved D1553.49 (SI Ap-
pendix, Fig. S4C). This salt bridge coordinates the conformation
of R170ICL2 such that R170ICL2 attracts the negatively charged
carboxylate group of D350Gαi5 (D-5, where “-5” indicates the
fifth residue counting from the C terminus of the Gα subunit) to
make a persistent salt bridge (SI Appendix, Fig. S4G). This also
induces D-5 to establish a polar interaction with the hydroxyl
group of T942.39 (SI Appendix, Fig. S4F). T942.39 also makes
polar contacts with the side chain of R170ICL2 (SI Appendix, Fig.
S4 D and E). This arginine is a conserved residue in all close
subtypes of opioid receptors (SI Appendix, Table S2). The cryo-
EM structure of μOR–Gi protein also shows that the analogous
R179ICL2 makes a polar contact with the D3.49 and most likely
establishes a salt bridge with D-5 (13). The behavior of
R179ICL2 in the μOR–Gi complex is consistent with the role that
its analog plays in the κOR–Gi structure. Indeed, we find that
R179ICL2 engages in a salt bridge with D-5 in our optimized
μOR–BU72–Gi complex (SI Appendix, Fig. S6E).
Eventually, the Gαi5 terminal carboxylate (F-1) is coupled to
the positively charged side chain of R2716.32 (Fig. 3F and SI
Appendix, Fig. S4P). The R2716.32 side chain was not resolved in
the crystal structure (7). Although this salt bridge is reasonably
stable during the MD simulation, it sometimes becomes a water-
mediated interaction. Therefore, to assess the strength of this
affinity, we used metaMD simulation (SI Appendix, Fig. S8L) to
find that emergence of the salt bridge stabilizes the complex by
reducing the energy by ∼1.5 kcal/mol. This moderate level of
binding shows why this charge–charge interaction occasionally
switches to a water-mediated interaction. Remarkably, the Gαi5
terminal carboxylate in our optimized μOR–BU72–Gi complex
involves polar interactions with R2776.32 and N2746.29. Aside
from this, D341 (D-10) on the Gαi5 also couples to R257 on the
ICL3, which consequently coordinates K345 (K-6) to form a
hydrogen bond with Y320 on the RAS-like region.
MP1104 Agonist Binding. The presence of Gi protein alters the
binding of MP1104 but it does not change the total nonbonded
interaction energies compared to the complex stabilized by Nb39
(SI Appendix, Fig. S9 A and B and Table S3). We find that the
MP1104 agonist binds to the κOR orthosteric pocket, where
strong polar interactions lock MP1104 into the human κOR (Fig.
4 A and B and SI Appendix, Figs. S10 and S11 and Table S3). SI
Appendix, Fig. S10 shows the pharmacophore of the binding
sites. The MP1104 agonist primarily engages in a strong and
persistent salt bridge from its positively charged amine moiety to
the carboxylate group of D1383.32 (Fig. 4 A and B and SI Ap-
pendix, Figs. S10 A and B and S11F and Table S3). D3.32 is
conserved in all close subtypes of opioid receptors (SI Appendix,
Table S2), playing a crucial role in stabilizing the orientation of
agonists and antagonists (7, 12, 13, 32–35). In particular, D3.32 is
an anchoring point for antagonist and agonist association to the
κOR binding pocket (36). Here, this salt bridge coordinates the
carboxylate group of D1383.32 to form a hydrogen bond with
Y3207.43 (Fig. 4 and SI Appendix, Figs. S10 and S11E). This
hydrogen bond was also identified in the active state κOR–Nb39
complex (7) (SI Appendix, Table S3). Indeed, the corresponding
link was also observed for the mouse μOR bound to BU72 (12).
Tyr7.43 plays a crucial role in mediating the binding pocket of the
μOR, since it participates in the TM3–TM7 microswitch. Mutating
Y3287.43 to a Phe dramatically reduces morphine binding affinity
(37). We find that MP1104 is further stabilized by forming two
hydrogen bonds from furan and carbonyl oxygen atoms to the
Y1393.33 hydroxyl group (Fig. 4 A and B and SI Appendix, Figs. S10
and S11 G and H). Another important polar interaction emerges
from the Y3127.35 hydroxyl group to the MP1104 aromatic ring (SI
Appendix, Fig. S11 K and L).
Aromatic interactions between MP1104 and κOR reinforce
the agonist binding affinity. H2916.52 has an essential role in
Fig. 3. Structure of the human κOR–GiP–MP1104 complex derived from our MD simulations using the Amber14 force field. (A) A side view of the κOR–GiP–
MP1104 complex. Cartoon views colored by subunit (blue, κOR; pink, Gαi; green, Gβi; red, Gγi); MP1104 is shown with van der Walls balls. Yellow indicates the
missing amino acid residues 56 to 181 and 234 to 240 in the Gα subunit in the cryo-EM (PDB ID: 6DDF) that we added in the simulation. This system contains
∼151 K atoms including: proteins, ligand, 277 POPC, and ∼32,000 water molecules as well as 98 Na+ and 100 Cl−. (B) Interaction between Gαi and ICL2 of κOR.
(C) Interaction of Gαi5 helix with TM2, TM3, and ICL2 of κOR. (D) Interaction between Gβi and ICL1 of κOR. (E) Interaction of Gαi with the bottom of κOR TM6
and ICL3. (F) Interaction of Gαi5 helix with ICL3 and TM6 of κOR.
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creating and regulating the aromatic network interactions. The
H2916.52 aromatic N atoms make aromatic contacts with the
MP1104 ring (Fig. 4A and SI Appendix, Figs. S11 A and B and
S11 C and D). H2916.52 also induces W2876.48 to move toward
MP1104. As a result of this movement, W2876.48 makes strong ar-
omatic contacts with H2916.52 (Fig. 4B and SI Appendix, Figs. S10 A
and B and S1B) and also forms a π–π stacking with the MP1104
aromatic ring (SI Appendix, Fig. S11A). This network of aromatic
interactions stabilizes the conformation of W2876.48, (χ1 ∼ −70°
(gauche+) and χ2 ∼110° (gauche−)) and H2916.52, (χ1 ∼ −79°
(gauche+) and χ2 ∼ −69° (gauche+)) (SI Appendix, Fig. S12 A–D).
The same χ2 value was reported for the activated structure of the
mouse μOR bound to BU72 (12). W2876.48 has been shown to play
a key part in the activation of A2aAR (38) and rhodopsin (39).
Discussion
Our MD simulations reveal that after G protein recruitment to
the GPCR, there is a further contraction in the GPCR binding
site while there is increased expansion in the cytosolic region of
GPCR that facilitates stabilizing the complex by creating the
extensive interactions from G protein to the cytoplasmic region
of GPCR. These remarkable rearrangements of the κOR by G
protein, transform the receptor toward its actual activated state.
These GPCR structural changes are consistent with the con-
served activation mechanism for many class A GPCRs (20–23),
where the expansion of the intracellular part of the GPCR co-
incides with contraction of the GPCR binding site. Therefore,
our finding suggests that Nb39 is able to shift κOR structure
from the inactive state up to an intermediate state, where the
cytoplasmic region is not fully open, and the binding site is not
fully contracted.
Our simulations show that anchors from the G protein to κOR
are essential for activation of κOR and for stabilizing the active
state complex. Our final active state complex includes two main
interactions: 1) strong anchors from the G protein to both ICL1
and ICL2 and to the end of TM6; and 2) extensive interactions
from the Gαi5 helix to the cytoplasmic region of κOR.
It is generally thought that Gαi5 helix has a pivotal role in
stabilizing the active state GPCR–G protein complex. However,
we have shown that anchors along with extensive interactions
from Gαi5 evolve the structure to reach the final activated state,
indicating the significant and perhaps essential role of anchors
for activating κOR. This discovery of the role of anchors provides
insight into the activation mechanism. It speculates that the ag-
onist binds first to inactive GPCR to partially open up the cy-
toplasmic region by opening TM3–TM6 coupling. In this
scenario, the Gi protein then approaches the GPCR by forming
anchors to ICL1, ICL2, and the end of TM6. At this stage, the
role of three anchors would align the Gαi5 helix just right to be
inserted into the GPCR. Once Gαi5 helix gets inserted into the
GPCR, it further opens up the distance between TM3 and TM6
to establish extensive polar interactions. Further expansion in the
cytoplasmic region of GPCR coincides with further contraction
of the GPCR binding site.
Given the strength of the three anchors, this suggests that the
G protein binds firsts, opening the TM3–6 coupling and partially
inserting the Gαi5 helix, followed by agonist binding to complete
the activation. This provides an alternative scenario to the gen-
erally accepted mechanism in which agonist binds first and re-
cruits the G protein to be activated.
Besides, we also proposed an approach to predict a high-
resolution structure of G protein–GPCR–agonist complex, us-
ing available GPCR structures that already were crystalized by an
active-state stabilizing nanobody. The resulting high-resolution
structures definitely facilitate discovery of new drugs acting on
GPCRs for different applications.
Methods
Refining the Activated Human κOR in Complex with MP1104 Agonist. A total of
31 residues were not fully resolved in the crystal structure of human κOR
bound to MP1104 agonist (PDB ID: 6B73) (7), including L51, I54, R86, S188,
S192, K200, V201, R202, D206, V207, D216, D217, M226, L251, K254, R257,
S262, R263, E264, K265, R267, L269, R270, R271, E297, T302, S305, I328, L329,
M336, and R339. Of these residues, R257, S262, and R271 engage in im-
portant polar interactions with Gi protein. We added these missing atoms/
side chains using Swiss-Pdbviewer (40), where during the process we also
reconstructed the side chains. Then, we replaced the engineered κOR N
terminus with the native residues from UNIPROT ID: 41145. We also removed
the T4L protein and added the amino acid sequence of ICL3 instead. We
reconstructed the disulfide bridge between C1313.25 and C210 of EC2 man-
ually by selecting new rotamers for these residues to have perpendicular Cβ-
S-S-Cβ dihedral angles. Then, we subjected these conformations to 10 cycles
of simulated annealing, in which all of the residues in the loops were heated
from 50 to 600 K and cooled back to 50 K over 10 ps of simulation. We
repeated this heat-and-quench cycle 10 times. During this process, all other
residues in TM domains were fixed. We extracted the final structure of this
process for further minimization. Subsequently, we exploited SCREAM (14)
and GEnSeMBLE (41) methods to refine the side chain of all residues in order
to obtain the minimized structure. We used this minimized structure for
building the κOR–Gi protein complex.
Gi Protein Preparation. The following 35 residues were not fully resolved or
were missing in the cryo-EM structure (PDB ID: 6DDF): residues L5, E28, E43,
I55, E207, N241, K270, E275, K279, K280, I285, C305, E308, E318, T327, D337,
and D350 in Gαi; residues K23, C25, S31, R46, E130, R214, M217, N237, C271,
N237, C271, K301, D312, and C317 in Gβi; and residues D26, D48, S57, and
E58, in Gγi.
Fig. 4. Comparison of MP1104 agonist binding interactions with the active state κOR in complex with the Gi protein (golden) and Nb39 (green). (A) Ex-
tracellular view. (B) Side view. The amino acid residues and MP1104 in the crystal structure of κOR–Nb39 is described by a wire scheme. Our nucleotide-free Gi
protein, water, and ions from the κOR–Gi protein complex, and Nb39 as well T4L fusion proteins from the crystal structure (PDB ID: 6B73) are omitted for the
sake of clarity.
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Of these residues, E308Gαi, E318Gαi, and D312Gβi involve forming anchors
with ICLs of κOR. We added these missing residues using Swiss-Pdbviewer
(40), where during the process we also reconstructed the side chains.
The entire amino acid residues in the AH domain of the Gαi subunit (PDB
ID: 6DDF) (13), residues 56 to 181 and 234 to 240, were all missing. These
missing residues were added by superimposing the cryo-EM structure of Gαi
complexed with rhodopsin (PDB ID: 6CMO) (16) to the cryo-EM structure of
Gαi complexed with the mouse μOR. We used the Needleman–Wunsch se-
quence alignment algorithm (42) with the BLOSUM-62 matrix, which is in-
corporated in the UCSF chimera software package (43). Then, we minimized
the structure including the connections between residues in Ras-like and AH
domains using the conjugated gradients method with 500 steps. During the
energy minimization process, all heavy atoms in the Ras-like domain were
restrained with a strong harmonic force constant of ∼24 kcal·mol−1·Å−2 to
avoid any undesirable changes in the original structure of Gαi.
Eventually, we extended the sequence of residues in the N terminus of the
Gαi, and C terminus of the Gγi using Prime (Schrödinger) in order to add the
N-terminal myristoyl, as well as C-terminal geranylgeranyl to Gαi and Gγi,
respectively.
Modeling of Human κOR–MP1104–Nb39 Complex. To build a complex we used
chain A of the crystal structure, but we had to make two modifications: 1) we
replaced the T4L protein with the native ICL3 sequence because T4L was not
resolved or provided. 2) Since there are missing residues/parts in the Nb39 of
chain A, we modeled the missing parts, mostly backbone atoms, using the
Nb39 structure provided in chain B. To do this, we superimposed two Nb39
structures and then added the required residues to fill the gaps in the Nb39 of
chain A. Subsequently, we fixed these missing atoms/side chains using Swiss-
Pdbviewer (40), where during the process we also reconstructed the side
chains. Eventually, we replaced our modified human κOR to the one pro-
vided in the crystal structure.
Modeling of Human κOR–MP1104–Gi Complex. To build a complex, we super-
imposed the refined human κOR–MP1104 to the refined cryo-EM structure of
mouse μOR–DAMGO–Gi using the Needleman–Wunsch sequence alignment
algorithm (42). To locate and optimize the interactions between human κOR
and Gi protein, we performed 1 ns (50 cycles) of simulated annealing, in which
the system was heated from 25 to 600 K with a sequence of 25, 100, 310, 450,
600 and cooled back to 310 K over 50 ps of simulation. In this calculation, we
placed harmonic restraints on all backbone and agonist heavy atoms with a
force constant of ∼9.6 kcal·mol−1·Å−2. However, to optimize the conformation
of the ICL3, no restraints were placed on the backbone atoms.
System Environment Preparation. We used our preequilibrated palmitoyl-oleoyl-
phosphatidylcholine (POPC) bilayer structure (44), which was used to study
the interaction between human somatostatin receptor 5 (h-SSTR5) and Gi
protein. To exploit this preequilibrated lipid structure, including 277 POPC
molecules, we aligned the refined human κOR–MP1104–Gi and human κOR–
MP1104–Nb39 to the h-SSTR5. Subsequently, we used GROMACS to place the
membrane and protein in a cubic box of 100 × 100 × 150 A3 in such a way that
the extracellular region above the POPC membrane was filled with ∼2 nm thick
preequilibrated water slab at 298 K (45). The intracellular region below the
membrane bilayer was also filled with preequilibrated water. Then, sodium
and chloride ions were added to maintain the electronic neutrality of the
system at a salt concentration of 100 mM. The final box contained ∼32,300
water molecules.
All molecules were parameterized using Amber force fields during sim-
ulations. The behavior of proteins was described by the Amber14 (46) and
parameters for the POPC were borrowed from the LIPID17, which is in-
corporated in Ambertools 16 (47). The parameters to treat the N-terminal
myristoyl and C-terminal geranylgeranyl were borrowed from the studies by
van Keulen et al. (48), and Khouri et al. (49), respectively. The carboxy-
methylation of the lipid linkages as well as the ligand, MP1104, were de-
scribed by the parameters obtained from the generalized Amber force field
(GAFF) (50) using ACPYPE (51) and Antechamber16 (52). The partial charges
for these two were assigned with the semiempirical AM1-BCC model (53),
which is incorporated in UCSF chimera (43). Water was described by the
TIP3P (54) model.
To examine whether our findings are independent from the applied force
field, we also carried out a separate equilibration on the human κOR–
MP1104–Gi complex using the Charmm36m force field. For this calculation,
proteins including their lipid linkage, POPC, ions, were described by the
parameters set by Charmm36m (55). Water was described by the TIP3P (54)
model. The ligand was parameterized by the ParamChem server (56, 57).
Equilibration. Subsequent to the preequilibration steps that are described in SI
Appendix, we extracted the trajectory at ∼61 ns that corresponds to the
minimum of free energy resulting from step 6 (SI Appendix). We included
the N-terminal myristoyl to Gαi and C-terminal geranylgeranyl to Gγi. Then,
we minimized the systems including κOR–MP1104–Gi, κOR–MP1104–Nb39,
and κOR–MP1104–Gi (Charmm36m), by 5,000 steps of energy minimization
with the steepest descent algorithm. Subsequently, we prepared these sys-
tems for the final equilibration by performing short NVT (constant particles,
volume, and temperature) for ∼75 ps, and NPT (constant number of parti-
cles, pressure, and temperature) for ∼350 ps, MD simulations, where posi-
tional restraints were placed on the heavy atoms with a force constant of
9.6 kcal·mol−1·Å−2 and gradually reduced to 0 kcal·mol−1·Å−2 during the course
of simulations. Eventually, we carried out a 200 ns of NPT simulation on
κOR–MP1104–Gi, κOR–MP1104–Nb39 structures and a 150-ns NPT simulation
on the κOR–MP1104–Gi (Charmm36m), without applying any restraints on
the structures to relax the systems and also examine the stability of inter-
actions. We used the results of these MD simulations for analyzing and
producing the figures in this study. We also repeated the same procedures
three additional times on the κOR–MP1104–Gi complex using Amber14.
Besides, in order to have a fair comparison between the MP1104 binding
pose in the presence of Gi and Nb39, we performed another round of en-
ergy minimization followed by preparations and final equilibration (30-ns
MD simulations) on the κOR–MP1104–Nb39 complex, to make sure the
MP1104 binding pose obtained from the crystal structure was not changed
significantly due to the modifications that we made.
Conclusion
We report the discovery that G protein makes strong anchors to
the three intracellular loops of κOR, which modifies the agonist
binding site and orients the Gαi5 helix for insertion upon acti-
vation. This binding site may be very useful for designing new
selective agonists for κOR and for determining how different the
binding sites are for biased versus nonbiased ligands to κOR.
The very specific predictions of the residues involved in
forming the anchors should provide numerous targets for mu-
tational studies to validate and refine the predicted anchors
between the G protein and κOR.
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